A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Registration Number
- NCT05283720
- Lead Sponsor
- Genmab
- Brief Summary
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 394 adult participants with NHL will be enrolled in 100 sites globally.
In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28-day or 21 day cycles dependent on the arm in combination with the anti-neoplastic agents described below:
1: Oral lenalidomide in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in participants with with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in participants with newly diagnosed treatment-naïve DLBCL; 4: Oral CC-99282 in participants with R/R DLBCL; 5: Oral CC-99282 in participants with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in participants with R/R mantle cell lymphoma (MCL); 6B: Oral ibrutinib, and oral venetoclax in participants with R/R MCL; 7: Oral ibrutinib, and oral venetoclax in participants with newly diagnosed treatment-naïve MCL.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 394
-
Diagnosis of:
-- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report:
- DLBCL, not otherwise specified (NOS).
- High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOS or other double- /triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible.
- Follicular lymphoma (FL) Grade 3B. OR
-
FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy, according to WHO 2016 classification. OR
-
Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at most recent representative tumor biopsy according to the WHO 2016 classification with evidence of overexpression of cyclin D1 in association with relevant markers or evidence of t(11;14) assessed by flow cytometry, FISH, or polymerase chain reaction (PCR).
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arms 6 and 7 where ECOG performance status must be 0-1.
-
Must have 1 or more measurable disease sites:
- A positron emission tomography (PET) /computed tomography (CT) scan demonstrating PET-positive lesion(s) AND
- At least 1 measurable nodal lesion (long axis > 1.5 cm) or >= 1 measurable extra-nodal lesion (long axis > 1.0 cm) on CT scan or magnetic resonance imaging (MRI).
- Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20.
- Toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with the exception of alopecia. Other eligibility criteria (e.g., laboratory, cardiac criteria) must also be met.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Arm 7: Dose Escalation Ibrutinib Participants with newly diagnosed treatment-naïve MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 1: Dose Escalation Epcoritamab Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of subcutaneous (SC) epcoritamab in combination with oral lenalidomide in 28 day cycles. Arm 1: Dose Escalation Lenalidomide Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of subcutaneous (SC) epcoritamab in combination with oral lenalidomide in 28 day cycles. Arm 2: Dose Escalation Epcoritamab Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles. Arm 2: Dose Escalation Lenalidomide Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles. Arm 2: Dose Escalation Ibrutinib Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles. Arm 3: Dose Escalation Doxorubicin Hydrochloride [HCl] Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 4: Dose Escalation CC-99282 Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 5: Dose Escalation CC-99282 Participants with R/R follicular lymphoma (FL) will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 5: Dose Expansion CC-99282 Participants with R/R FL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 3: Dose Expansion Doxorubicin Hydrochloride [HCl] Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 4: Dose Expansion CC-99282 Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 6: Dose Expansion Epcoritamab Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib in 28 day cycles. Arm 6: Dose Expansion Ibrutinib Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib in 28 day cycles. Arm 7: Dose Expansion Epcoritamab Participants with newly diagnosed treatment-naïve MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 7: Dose Expansion Ibrutinib Participants with newly diagnosed treatment-naïve MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 7: Dose Expansion Venetoclax Participants with newly diagnosed treatment-naïve MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 8: Dose Expansion Epcoritamab Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral pirtobrutinib in 28 day cycles in the first year and then 56 day cycles thereafter. Arm 8: Dose Expansion Pirtobrutinib Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral pirtobrutinib in 28 day cycles in the first year and then 56 day cycles thereafter. Arm 3: Dose Escalation Prednisone Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 3: Dose Escalation Epcoritamab Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 3: Dose Escalation Cyclophosphamide Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 3: Dose Escalation Rituximab Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 3: Dose Escalation Polatuzumab Vedotin Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 4: Dose Escalation Epcoritamab Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 5: Dose Escalation Epcoritamab Participants with R/R follicular lymphoma (FL) will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 6A: Dose Escalation Ibrutinib Participants with R/R mantle cell lymphoma (MCL) will receive escalating doses of SC epcoritamab in combination with oral ibrutinib in 28 day cycles. Arm 6A: Dose Escalation Epcoritamab Participants with R/R mantle cell lymphoma (MCL) will receive escalating doses of SC epcoritamab in combination with oral ibrutinib in 28 day cycles. Arm 6B: Dose Escalation Epcoritamab Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 6B: Dose Escalation Ibrutinib Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 7: Dose Escalation Epcoritamab Participants with newly diagnosed treatment-naïve MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 6B: Dose Escalation Venetoclax Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 2: Dose Expansion Lenalidomide Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles. Arm 7: Dose Escalation Venetoclax Participants with newly diagnosed treatment-naïve MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles. Arm 8: Dose Escalation Epcoritamab Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral pirtobrutinib in 28 day cycles in the first year and then 56 day cycles thereafter. Arm 8: Dose Escalation Pirtobrutinib Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral pirtobrutinib in 28 day cycles in the first year and then 56 day cycles thereafter. Arm 1: Dose Expansion Epcoritamab Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral lenalidomide in 28 day cycles. Arm 1: Dose Expansion Lenalidomide Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral lenalidomide in 28 day cycles. Arm 2: Dose Expansion Epcoritamab Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles. Arm 3: Dose Expansion Epcoritamab Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 2: Dose Expansion Ibrutinib Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles. Arm 3: Dose Expansion Rituximab Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 3: Dose Expansion Polatuzumab Vedotin Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 4: Dose Expansion Epcoritamab Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles. Arm 3: Dose Expansion Cyclophosphamide Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 3: Dose Expansion Prednisone Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles. Arm 5: Dose Expansion Epcoritamab Participants with R/R FL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
- Primary Outcome Measures
Name Time Method Number of Participants with Dose-Limiting Toxicities (DLT) Up to Approximately 5 Years DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) Up to Approximately 5 Years (OS) is defined as the time in months from first dose of epcoritamab to death from any cause.
Rate of Minimal Residual Disease (MRD) Negativity Up to Approximately 5 Years MRD is defined as the percentage of participants with assessment of the minimal residual disease.
Best Overall Response (BOR) per Investigator Up to Approximately 5 Years BOR is defined as the percentage of participants who achieved best overall response of CR or PR by Lugano 2014 criteria as assessed by the investigator.
Duration of response (DOR) per Investigator Up to Approximately 5 Years DOR is defined for participants who achieved best overall response of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of radiographic progression determined by Lugano 2014 criteria as assessed by the investigator, or death from any cause.
Number of Participants with Progression-free survival (PFS) Up to Approximately 5 Years PFS is defined as the time in months from the first dose of study drug to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
Percentage of Participants with Complete Response (CR) Up to Approximately 5 Years CR is defined as the percentage of participantswho achieved best overall response of CR determined by Lugano 2014 criteria as assessed by investigator.
Time-to-response (TTR) Up to Approximately 5 Years TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by investigator.
Time to Next Antilymphoma Therapy (TTNT) Up to Approximately 5 Years Time to next antilymphoma therapy.
Trial Locations
- Locations (74)
Hospital Universitario 12 de Octubre /ID# 243262
🇪🇸Madrid, Spain
Debreceni Egyetem-Klinikai Kozpont /ID# 242450
🇭🇺Debrecen, Hajdu-Bihar, Hungary
Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 245935
🇭🇺Kaposvár, Somogy, Hungary
Orszagos Onkologiai Intezet /ID# 242458
🇭🇺Budapest, Hungary
The Chaim Sheba Medical Center /ID# 243010
🇮🇱Ramat Gan, Tel-Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 243012
🇮🇱Tel Aviv, Tel-Aviv, Israel
Hadassah Medical Center-Hebrew University /ID# 243013
🇮🇱Jerusalem, Yerushalayim, Israel
Rabin Medical Center /ID# 243014
🇮🇱Petah Tikva, Israel
Hokkaido University Hospital /ID# 248999
🇯🇵Sapporo-shi, Hokkaido, Japan
Kyoto University Hospital /ID# 248997
🇯🇵Kyoto-shi, Kyoto, Japan
National Cancer Center Hospital /ID# 248995
🇯🇵Chuo-ku, Tokyo, Japan
Seoul National University Bundang Hospital /ID# 242404
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Seoul National University Hospital /ID# 242402
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Asan Medical Center /ID# 242400
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Samsung Medical Center /ID# 242401
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242403
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Maastricht Universitair Medisch Centrum /ID# 243317
🇳🇱Maastricht, Limburg, Netherlands
Vrije Universiteit Medisch Centrum /ID# 243319
🇳🇱Amsterdam, Noord-Holland, Netherlands
Leids Universitair Medisch Centrum /ID# 243316
🇳🇱Leiden, Zuid-Holland, Netherlands
Duplicate_Erasmus Medisch Centrum /ID# 243315
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Universitair Medisch Centrum Groningen /ID# 243318
🇳🇱Groningen, Netherlands
Instituto Catalan de Oncologia (ICO) Badalona /ID# 243265
🇪🇸Badalona, Barcelona, Spain
Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 243261
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Clinica Universidad de Navarra - Pamplona /ID# 245031
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario Vall d'Hebron /ID# 243260
🇪🇸Barcelona, Spain
CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 243268
🇪🇸Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz /ID# 243264
🇪🇸Madrid, Spain
Hospital Universitario de Salamanca /ID# 243368
🇪🇸Salamanca, Spain
Hospital Universitario Virgen del Rocio /ID# 243267
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Valencia /ID# 243269
🇪🇸Valencia, Spain
China Medical University Hospital /ID# 242893
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital /ID# 242894
🇨🇳Tainan, Taiwan
Taipei Veterans General Hosp /ID# 242892
🇨🇳Taipei, Taiwan
University of Arizona Cancer Center - North Campus /ID# 242219
🇺🇸Tucson, Arizona, United States
Emory University /ID# 242153
🇺🇸Atlanta, Georgia, United States
University of Maryland, Baltimore /ID# 242218
🇺🇸Baltimore, Maryland, United States
Novant Health Presbyterian Medical Center /ID# 242148
🇺🇸Charlotte, North Carolina, United States
East Carolina University - Brody School of Medicine /ID# 242506
🇺🇸Greenville, North Carolina, United States
Yale University School of Medicine /ID# 242089
🇺🇸New Haven, Connecticut, United States
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144
🇺🇸Kansas City, Missouri, United States
Christiana Care Health Service /ID# 242301
🇺🇸Newark, Delaware, United States
Tampa General Hospital /ID# 246748
🇺🇸Tampa, Florida, United States
Northwell Health - Monter Cancer Center /ID# 245435
🇺🇸Lake Success, New York, United States
Thomas Jefferson University Hospital /ID# 242077
🇺🇸Philadelphia, Pennsylvania, United States
Thompson Cancer Survival Ctr /ID# 242150
🇺🇸Knoxville, Tennessee, United States
Joe Arrington Cancer Research /ID# 242226
🇺🇸Lubbock, Texas, United States
Icahn School of Medicine at Mount Sinai /ID# 242123
🇺🇸New York, New York, United States
MultiCare Institute for Research & Innovation /ID# 242127
🇺🇸Tacoma, Washington, United States
Novant Health Forsyth Medical Center /ID# 242198
🇺🇸Winston-Salem, North Carolina, United States
Fox Chase Cancer Center /ID# 242106
🇺🇸Philadelphia, Pennsylvania, United States
Swedish Cancer Institute /ID# 242269
🇺🇸Seattle, Washington, United States
Fakultní Nemocnice Brno - Jihlavská /ID# 242683
🇨🇿Brno, Brno-mesto, Czechia
Fakultní nemocnice Hradec Králové - Sokolská /ID# 241722
🇨🇿Hradec Králové, Hradec Kralove, Czechia
Fakultni Nemocnice Ostrava /ID# 242684
🇨🇿Ostrava, Ostrava-mesto, Czechia
Vseobecna fakultni nemocnice v Praze /ID# 242685
🇨🇿Praha, Czechia
Aarhus Universitetshospital - Skejby /ID# 242670
🇩🇰Aarhus, Midtjylland, Denmark
Aalborg University Hospital /ID# 242734
🇩🇰Aalborg, Nordjylland, Denmark
CHU Clermont-Ferrand /ID# 242344
🇫🇷Clermont, Auvergne-Rhone-Alpes, France
CHU de Rennes - PONTCHAILLOU /ID# 242339
🇫🇷Rennes, Bretagne, France
Hopital Pitie Salpetriere /ID# 242343
🇫🇷Paris, Ile-de-France, France
CHRU Nancy - Hopitaux de Brabois /ID# 242342
🇫🇷Vandoeuvre-les-Nancy, Meurthe-et-Moselle, France
CHRU Lille - Hopital Claude Huriez /ID# 242335
🇫🇷Lille, Nord, France
IUCT Oncopole /ID# 242340
🇫🇷Toulouse Cedex 9, Occitanie, France
CHU de Nantes, Hotel Dieu -HME /ID# 242345
🇫🇷Nantes, Pays-de-la-Loire, France
Hôpital Saint-Louis /ID# 242336
🇫🇷Paris, France
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 242337
🇫🇷Creteil, Paris, France
HCL - Hopital Lyon Sud /ID# 242349
🇫🇷Pierre Benite CEDEX, Rhone, France
Universitaetsklinikum Ulm /ID# 244265
🇩🇪Ulm, Baden-Wuerttemberg, Germany
Universitaetsklinikum Giessen und Marburg /ID# 245308
🇩🇪Marburg, Hessen, Germany
Universitaetsklinikum Leipzig /ID# 245513
🇩🇪Leipzig, Sachsen, Germany
Klinikum Augsburg /ID# 244523
🇩🇪Augsburg, Bayern, Germany
Universitaetsklinikum Wuerzburg /ID# 245453
🇩🇪Wuerzburg, Bayern, Germany
Universitaetsklinikum Regensburg /ID# 244517
🇩🇪Regensburg, Germany
Semmelweis Egyetem /ID# 242454
🇭🇺Budapest, Hungary